There are truths in biology that reveal themselves much like hidden tributaries feeding a great river — subtle at first glance, yet essential to the current’s direction. In the story of cancer — a disease that has long vexed patients and physicians alike — researchers are now looking more closely at a tiny group of cells within tumors that appear to shape much of what comes after: progression, spread, and resistance to treatment. These are not the majority of tumor cells, but a special subset whose flexibility, or “plasticity,” allows them to adapt and endure even through some of the most aggressive therapies.

In studies led by scientists at Memorial Sloan Kettering and affiliated institutions, these highly plastic cells are described as having an almost regenerative program — a way of changing their identity that resembles the body’s own injury-healing processes. Unlike the bulk of tumor cells, which may follow predictable pathways, these plastic cells can shift states, give rise to rapidly growing progeny, and survive assaults that kill their neighbors. In early lesions, they may be a small minority — a few percent of all cells — but as tumors grow and especially as they spread to other organs, their presence can rise markedly.

This adaptability is not merely a biological curiosity; it is central to how a tumor evolves in the face of treatment. When chemotherapy or targeted drugs attack a tumor, most cancer cells may die, yet the plastic subset can transition into drug-tolerant forms, preserving a core of disease that may later regrow. This is why two tumors that begin similarly can end very differently — like seeds carried by wind, landing in soils of varying readiness to nurture new life.

Instead of arising from traditional gene mutations alone, these highly plastic states seem to be driven by changes in gene expression and cellular programs that allow cells to “switch tracks” in response to stress. In detailed lab models, researchers have even identified unique markers on these cells, offering a glimpse of how they might be targeted more effectively in future therapies. In mice, therapies designed to eliminate these plastic cells led to slower tumor growth and reduced resistance, opening a promising path toward improving outcomes.

Understanding this dynamic — that a small portion of highly adaptable cells can dictate the broader fate of a tumor — feels like discovering a crucial junction on a map you thought you already knew well. It underscores that progress against cancer might come not only from killing as many cancer cells as possible, but also from preempting the creative, adaptive forces within the tumor itself.

In recent experimental studies, scientists found that a minor population of highly plastic cancer cells within tumors drives disease progression and contributes to resistance against conventional treatments. These cells show a capacity to adapt dynamically, increasing in proportion as tumors grow and survive therapy, suggesting that targeting plasticity could enhance treatment effectiveness.

AI Image Disclaimer “Visuals are created with AI tools and are not real photographs.”

Sources

Memorial Sloan Kettering Cancer Center research on highly plastic cells driving progression and resistance EurekAlert! science press release summarizing the findings PubMed literature on cellular plasticity and therapy resistance Scientific reviews on tumor heterogeneity and adaptive resistance mechanisms Context from research summaries on cell plasticity’s role in tumor evolution and treatment challenges